Javascript must be enabled to continue!
Premature Ventricle Contraction Ablation in Cardiac Sarcoidosis
View through CrossRef
Abstract
Background
Premature ventricular contractions (PVCs) are common and often benign, but in patients with structural heart disease—including cardiac sarcoidosis (CS)—they may contribute to tachycardia-induced cardiomyopathy, malignant ventricular arrhythmias (VA), and sudden cardiac death. Catheter ablation (CA) is an established therapy for idiopathic PVCs, yet outcomes of PVC ablation in CS remain poorly defined.
Methods
We retrospectively reviewed consecutive patients with CS undergoing PVC ablation at the Medical University of South Carolina from January 2017 to December 2022. CS was diagnosed per Heart Rhythm Society criteria. Mapping and ablation were performed using CARTO 3 or EnSite NavX electroanatomic systems. Acute success was defined as elimination of clinical PVCs at the end of the procedure. Long-term outcomes included PVC burden reduction (> 80%), symptomatic improvement, ventricular arrhythmia-free survival, and transplant-free survival.
Results
Eleven patients (55% male, mean age 61 ± 12 years, mean LVEF 46% ± 15) underwent 13 ablation procedures targeting 17 clinically relevant PVCs. Acute elimination of PVCs was achieved in all patients without major procedural complications. During a mean follow-up of 927 ± 618 days, 8 of 11 patients (73%) achieved durable arrhythmia control. Mean PVC burden decreased from 33.5% ± 14 pre-ablation to 1.2% ± 0.4 post-ablation (p < 0.01), with a mean LVEF improvement of 6.8% ± 7.3. Three patients experienced recurrent PVCs, of whom one underwent repeat ablation. One patient developed sustained VT and ultimately required heart transplantation. Overall survival was 100%, and transplant-free survival was 91% at last follow-up.
Conclusions
PVC ablation in patients with CS is safe and acutely effective, with high rates of long-term arrhythmia suppression, improved ventricular function, and low incidence of subsequent malignant VA. Integration of multidisciplinary sarcoid-directed therapy alongside ablation likely contributes to favorable outcomes. PVC ablation should be strongly considered as part of a comprehensive management strategy in select CS patients.
Springer Science and Business Media LLC
Title: Premature Ventricle Contraction Ablation in Cardiac Sarcoidosis
Description:
Abstract
Background
Premature ventricular contractions (PVCs) are common and often benign, but in patients with structural heart disease—including cardiac sarcoidosis (CS)—they may contribute to tachycardia-induced cardiomyopathy, malignant ventricular arrhythmias (VA), and sudden cardiac death.
Catheter ablation (CA) is an established therapy for idiopathic PVCs, yet outcomes of PVC ablation in CS remain poorly defined.
Methods
We retrospectively reviewed consecutive patients with CS undergoing PVC ablation at the Medical University of South Carolina from January 2017 to December 2022.
CS was diagnosed per Heart Rhythm Society criteria.
Mapping and ablation were performed using CARTO 3 or EnSite NavX electroanatomic systems.
Acute success was defined as elimination of clinical PVCs at the end of the procedure.
Long-term outcomes included PVC burden reduction (> 80%), symptomatic improvement, ventricular arrhythmia-free survival, and transplant-free survival.
Results
Eleven patients (55% male, mean age 61 ± 12 years, mean LVEF 46% ± 15) underwent 13 ablation procedures targeting 17 clinically relevant PVCs.
Acute elimination of PVCs was achieved in all patients without major procedural complications.
During a mean follow-up of 927 ± 618 days, 8 of 11 patients (73%) achieved durable arrhythmia control.
Mean PVC burden decreased from 33.
5% ± 14 pre-ablation to 1.
2% ± 0.
4 post-ablation (p < 0.
01), with a mean LVEF improvement of 6.
8% ± 7.
3.
Three patients experienced recurrent PVCs, of whom one underwent repeat ablation.
One patient developed sustained VT and ultimately required heart transplantation.
Overall survival was 100%, and transplant-free survival was 91% at last follow-up.
Conclusions
PVC ablation in patients with CS is safe and acutely effective, with high rates of long-term arrhythmia suppression, improved ventricular function, and low incidence of subsequent malignant VA.
Integration of multidisciplinary sarcoid-directed therapy alongside ablation likely contributes to favorable outcomes.
PVC ablation should be strongly considered as part of a comprehensive management strategy in select CS patients.
Related Results
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
How to Use Imaging: Cardiac Sarcoidosis
How to Use Imaging: Cardiac Sarcoidosis
Sarcoidosis is characterized by noncaseating granulomatous inflammation that involves the lungs or lymph nodes in 90% of cases. The prevalence of cardiac involvement in patients wi...
Sarcoidosis
Sarcoidosis
Sarcoidosis is a systemic disease characterized by the presence of noncaseating granulomas, which accumulate in affected organs. The incidence, organ involvement, and disease sever...
Sarcoidosis
Sarcoidosis
Sarcoidosis is a systemic disease characterized by the presence of noncaseating granulomas, which accumulate in affected organs. The incidence, organ involvement, and disease sever...
Ablation Performance of C/SiC-ZrC Composites
Ablation Performance of C/SiC-ZrC Composites
Abstract
To reveal the ablation performance of C/SiC-ZrC composites under different ablation methods, C/SiC-ZrC composites were prepared by chemical vapor deposition and pr...
Genetic association of lipids and lipid-lowering drug target genes with sarcoidosis
Genetic association of lipids and lipid-lowering drug target genes with sarcoidosis
Abstract
Objective:
Todetermine the potential causal association between serum lipid levels and sarcoidosis, and to investigate the potential impact of lipid-lowering agent...
Drug‐induced sarcoidosis: an overview of the WHO pharmacovigilance database
Drug‐induced sarcoidosis: an overview of the WHO pharmacovigilance database
AbstractBackgroundThere is a documented association between drug exposure and sarcoidosis‐like reactions. In this study, we used the largest pharmacovigilance database to describe ...
Clinical significance of detection of mononuclear phagocyte subsets in blood and bronchoalveolar lavage fluid (BALF) in pulmonary sarcoidosis
Clinical significance of detection of mononuclear phagocyte subsets in blood and bronchoalveolar lavage fluid (BALF) in pulmonary sarcoidosis
This study aimed to investigate the clinical significance of the detection of mononuclear phagocytes subsets in pulmonary sarcoidosis blood and bronchoalveolar lavage fluid (BALF)....

